015IC - AUA Advanced Prostate Cancer Guidelines
214A
Instructional Course
Oncology: Prostate
Information
Learning Objectives
1. Identify appropriate use of genetic testing and genetic counseling.
2. Identify appropriate use of somatic testing and treatments related to specific genetic alterations.
3. Identify appropriate combination therapy with androgen deprivation therapy plus novel androgen access therapies and chemotherapy. Early treatment intensification will be discussed in metastatic hormone-sensitive prostate cancer.
4. Identify the treatments for nonmetastatic CRPC and oncologic outcomes based on AUA/SUO (Society of Urologic Oncology) Guidelines.
5. Cancel patients on available treatment options for CRPC as well as combination therapy and sequencing based on AUA/SUO Guidelines.
Course Description: This course will be comprehensive AUA Guidelines on advanced prostate cancer in the management and outcomes of men with advanced, metastatic and castrate-resistant prostate cancer (CRPC). The course will include risk stratification, germline testing, PET imaging, the use of androgen deprivation therapy in combination with novel androgen axis therapy and chemotherapy in men with newly diagnosed metastatic hormone-sensitive prostate cancer. Early treatment intensification and evidenced-based guidelines will be covered. The course will also cover nonmetastatic CRPC and treatment for metastatic CRPC. The use of sequencing, combination therapy, somatic testing and precision medicine with PARP inhibitors will also be discussed. The course will also cover emerging salvage therapies for CRPC.
1. Identify appropriate use of genetic testing and genetic counseling.
2. Identify appropriate use of somatic testing and treatments related to specific genetic alterations.
3. Identify appropriate combination therapy with androgen deprivation therapy plus novel androgen access therapies and chemotherapy. Early treatment intensification will be discussed in metastatic hormone-sensitive prostate cancer.
4. Identify the treatments for nonmetastatic CRPC and oncologic outcomes based on AUA/SUO (Society of Urologic Oncology) Guidelines.
5. Cancel patients on available treatment options for CRPC as well as combination therapy and sequencing based on AUA/SUO Guidelines.
Course Description: This course will be comprehensive AUA Guidelines on advanced prostate cancer in the management and outcomes of men with advanced, metastatic and castrate-resistant prostate cancer (CRPC). The course will include risk stratification, germline testing, PET imaging, the use of androgen deprivation therapy in combination with novel androgen axis therapy and chemotherapy in men with newly diagnosed metastatic hormone-sensitive prostate cancer. Early treatment intensification and evidenced-based guidelines will be covered. The course will also cover nonmetastatic CRPC and treatment for metastatic CRPC. The use of sequencing, combination therapy, somatic testing and precision medicine with PARP inhibitors will also be discussed. The course will also cover emerging salvage therapies for CRPC.
Of Interest To
Advanced Practice Providers/Allied Health Professionals
Continuing Medical Education
CME
Format
In PersonLive StreamOn Demand
Documents & Links
015IC - Course Materials